Rhythm Pharma insider plans 50K-share sale

David Meeker filed a Rule 144 notice to sell 50,000 RYTM common shares acquired by option exercise on or after September 14, 2026.

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS, INC. (RYTM) is the issuer for which David Meeker has filed a notice of proposed sale of restricted or control securities under Rule 144. The notice covers a proposed sale of 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,235,500 as of the filing. The filing lists 68,852,082 shares of common stock outstanding and indicates the shares are to be sold on NASDAQ on or after September 14, 2026, following acquisition via exercise of stock options for cash.

Key Figures

Shares to be sold: 50,000 shares of common stock Aggregate market value of shares to be sold: $5,235,500 Shares outstanding: 68,852,082 shares +1 more

4 metrics

Shares to be sold 50,000 shares of common stock Proposed sale under Rule 144 by David Meeker

Aggregate market value of shares to be sold $5,235,500 Value of 50,000 RYTM shares covered by the Rule 144 notice

Shares outstanding 68,852,082 shares Common stock outstanding referenced in the Form 144 for RYTM

Earliest sale date September 14, 2026 Date on or after which the 50,000 shares may be sold

Key Terms

Rule 144, Exercise of Stock Options, aggregate market value

3 terms

Rule 144 regulatory

"notice of proposed sale of restricted or control securities under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Securities To Be Sold: Common | 09/14/2026 | Exercise of Stock Options"

aggregate market value financial

"50,000 | 5,235,500.00 | 68,852,082 | 09/14/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is David Meeker planning under Rule 144 for RYTM?

David Meeker filed a Rule 144 notice for a proposed sale of 50,000 shares of RHYTHM PHARMACEUTICALS, INC. common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ on or after September 14, 2026.

What is the aggregate market value of the RYTM shares in this Form 144 filing?

The Form 144 lists an aggregate market value of approximately $5,235,500 for the 50,000 shares of RHYTHM PHARMACEUTICALS, INC. common stock covered by the notice, based on the market price at the time of the filing.

How many RHYTM shares are outstanding as referenced in this Form 144?

The Form 144 references 68,852,082 shares of RHYTHM PHARMACEUTICALS, INC. common stock outstanding, providing context for the proposed 50,000-share sale under Rule 144.

How will the RYTM shares in this Rule 144 filing be acquired for sale?

The shares covered by the notice are to be acquired via exercise of stock options for cash on September 14, 2026, and then may be sold under Rule 144 on NASDAQ through Morgan Stanley Smith Barney LLC.

Who is the broker for the planned RYTM Rule 144 sale?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, which is designated to handle the proposed sale of 50,000 RYTM common shares under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:56 PM Accepted by SEC EDGAR 09/14/2026 - 04:49 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001385155
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	RHYTHM PHARMACEUTICALS INC
SEC File Number	001-38223
Address of Issuer	222 Berkeley Street, 12th Floor BOSTON MASSACHUSETTS 02116
Phone	8572644280
Name of Person for Whose Account the Securities are To Be Sold	David Meeker
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	50000	5235500.00	68852082	09/14/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/14/2026	Exercise of Stock Options	Issuer			50000	09/14/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/14/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ David Meeker
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)